Merus N.V. (2GH.F)

41,40 -2,40 (-5,48%) Börsenschluss: 03:29PM CEST

Merus N.V.

Uppsalalaan 17
3rd & 4th floor
Utrecht 3584 CT
Netherlands
31 30 253 8800
https://www.merus.nl

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 172

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Sven Ante Lundberg M.D.	CEO, President & Executive Director	1,03M	N/A	1963
Mr. Gregory D. Perry	Chief Financial Officer	388,52k	N/A	1960
Mr. Peter B. Silverman J.D.	EVP, Company Secretary, COO, General Counsel, Chief Intellectual Property Officer & Head of US Legal	724,8k	523,8k	1978
Dr. Hui Liu Ph.D.	Chief Business Officer, Executive VP & Head of Merus U.S.	593,43k	1,67M	1967
Dr. Andrew Joe M.D.	Chief Medical Officer & Senior VP	635,13k	N/A	1967
Dr. Hennie Hoogenboom	Co-Founder and Scientific Advisor	N/A	N/A	N/A
Harry Shuman	Chief Accounting Officer	N/A	N/A	N/A
Mr. Cornelis Adriaan de Kruif Ph.D.	CTO & Executive VP	323,91k	N/A	1965
Dr. Cecilia Anna Wilhelmina Geuijen Ph.D.	Chief Scientific Officer & Senior VP	N/A	N/A	N/A
Kathleen Farren	IR & Corporate Communications Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Corporate Governance

Merus N.V.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.